Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04201262

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Neuromyelitis Optica Clinical Trial

Official title:
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Clinical Trial Summary

The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04201262
Study type Interventional
Source Alexion
Contact
Status Active, not recruiting
Phase Phase 3
Start date December 13, 2019
Completion date July 31, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02283671 - Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Phase 1
Recruiting NCT01024985 - Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct N/A
Recruiting NCT04601142 - Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism
Completed NCT03942952 - PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Recruiting NCT05573711 - Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
Not yet recruiting NCT06118398 - Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
Recruiting NCT05566769 - Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD N/A
Withdrawn NCT03829566 - Autologous Transplant To End NMO Spectrum Disorder Phase 2/Phase 3
Recruiting NCT05403138 - Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT03350633 - Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Recruiting NCT05356858 - An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients Phase 2
Recruiting NCT05982925 - Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Terminated NCT02398994 - A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Phase 3
Withdrawn NCT02087813 - Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Phase 1
Terminated NCT01339455 - Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Phase 1/Phase 2
Recruiting NCT02021825 - Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Phase 4
Active, not recruiting NCT04614454 - High Frequency Impulse Therapy for Neuropathic Pain in NMOSD Phase 2
Recruiting NCT03370965 - Optic Neuritis Differential Diagnosis Study N/A
Completed NCT01777412 - Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Phase 1